Two faces of SIVA

Lois Resnick-Silverman; James J. Manfredi

doi:10.1158/2159-8290.CD-15-0484

Two faces of SIVA

Lois Resnick-Silverman
, James J. Manfredi

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

In non–small cell lung cancer cells that contain a mutated KRAS gene, SIVA, a p53 target gene that is critical for apoptosis, is overexpressed in a p53-independent manner and promotes tumorigenesis through the stimulation of mTOR signaling. The ablation of Siva in conditional knockout mice results in an inhibition of tumor development that makes SIVA an interesting new candidate therapeutic target for the treatment of a carcinoma with few therapeutic options.

Original language	English
Pages (from-to)	581-583
Number of pages	3
Journal	Cancer Discovery
Volume	5
Issue number	6
DOIs	https://doi.org/10.1158/2159-8290.CD-15-0484
State	Published - Jun 2015

Access to Document

10.1158/2159-8290.CD-15-0484

Cite this

@article{82c30469b5204a45b535f290987127d8,

title = "Two faces of SIVA",

abstract = "In non–small cell lung cancer cells that contain a mutated KRAS gene, SIVA, a p53 target gene that is critical for apoptosis, is overexpressed in a p53-independent manner and promotes tumorigenesis through the stimulation of mTOR signaling. The ablation of Siva in conditional knockout mice results in an inhibition of tumor development that makes SIVA an interesting new candidate therapeutic target for the treatment of a carcinoma with few therapeutic options.",

author = "Lois Resnick-Silverman and Manfredi, \{James J.\}",

note = "Publisher Copyright: {\textcopyright} 2015 American Association for Cancer Research.",

year = "2015",

month = jun,

doi = "10.1158/2159-8290.CD-15-0484",

language = "English",

volume = "5",

pages = "581--583",

journal = "Cancer Discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - Two faces of SIVA

AU - Resnick-Silverman, Lois

AU - Manfredi, James J.

PY - 2015/6

Y1 - 2015/6

N2 - In non–small cell lung cancer cells that contain a mutated KRAS gene, SIVA, a p53 target gene that is critical for apoptosis, is overexpressed in a p53-independent manner and promotes tumorigenesis through the stimulation of mTOR signaling. The ablation of Siva in conditional knockout mice results in an inhibition of tumor development that makes SIVA an interesting new candidate therapeutic target for the treatment of a carcinoma with few therapeutic options.

AB - In non–small cell lung cancer cells that contain a mutated KRAS gene, SIVA, a p53 target gene that is critical for apoptosis, is overexpressed in a p53-independent manner and promotes tumorigenesis through the stimulation of mTOR signaling. The ablation of Siva in conditional knockout mice results in an inhibition of tumor development that makes SIVA an interesting new candidate therapeutic target for the treatment of a carcinoma with few therapeutic options.

UR - https://www.scopus.com/pages/publications/84980034361

U2 - 10.1158/2159-8290.CD-15-0484

DO - 10.1158/2159-8290.CD-15-0484

M3 - Article

C2 - 26037915

AN - SCOPUS:84980034361

SN - 2159-8274

VL - 5

SP - 581

EP - 583

JO - Cancer Discovery

JF - Cancer Discovery

IS - 6

ER -

Two faces of SIVA

Abstract

Access to Document

Fingerprint

Cite this